Citation Impact
Citing Papers
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
2017 Standout
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
2015
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
2015
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
2013
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Essential Roles of SATB1 in Specifying T Lymphocyte Subsets
2017 StandoutNobel
Development of metastatic HER2+ breast cancer is independent of the adaptive immune system
2010
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
2013
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
2013
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Localized cell stimulation by nitric oxide using a photoactive porous coordination polymer platform
2013 StandoutNobel
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
2011
A gene expression signature identifies two prognostic subgroups of basal breast cancer
2010
IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers
2014
Engineering precision nanoparticles for drug delivery
2020 Standout
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
2010
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
2016
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
QuPath: Open source software for digital pathology image analysis
2017 Standout
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
2016
Pancreatic cancer
2020 Standout
Ovarian cancer
2014 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Sphingolipids and their metabolism in physiology and disease
2017 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4
2017 StandoutNobel
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors
2012 Nobel
Lgr5-Expressing Cells Are Sufficient and Necessary for Postnatal Mammary Gland Organogenesis
2013
Nasopharyngeal carcinoma
2019 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer
2014
Why the stroma matters in breast cancer
2012
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Immune parameters affecting the efficacy of chemotherapeutic regimens
2011
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
2020
In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes
2014
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
2015
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
2015
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
2011
How the ageing microenvironment influences tumour progression
2019
Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2
2011
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
2013 Standout
Genome organizing function of SATB1 in tumor progression
2012
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers
2016 Standout
An “elite hacker”
2012
Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data
2012
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Modeling Development and Disease with Organoids
2016 Standout
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
2015
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Functional Characterization of Novel Mutations Affecting Survivin (BIRC5)-Mediated Therapy Resistance in Head and Neck Cancer Patients
2012
TIMER2.0 for analysis of tumor-infiltrating immune cells
2020 Standout
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Immune targeting in breast cancer.
2015
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
2013
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Prognostic and predictive value of PDL1 expression in breast cancer
2014
Natural product and natural product derived drugs in clinical trials
2014 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers
2010
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
2013
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
New Strategies in Breast Cancer: Immunotherapy
2016
Works of Lars Hanker being referenced
NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas
2008
Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer
2009
Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer
2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
2009
Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures
2011
SATB1 gene expression and breast cancer prognosis
2010
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
2010 Nobel
Acid Ceramidase (AC)—A Key Enzyme of Sphingolipid Metabolism—Correlates With Better Prognosis in Epithelial Ovarian Cancer
2013
Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer
2008
Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer
2009
A clinically relevant gene signature in triple negative and basal-like breast cancer
2011
Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors
2014
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
2011
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
2012
Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
2012
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
2011
The prognostic impact of age in different molecular subtypes of breast cancer
2015
Clinical relevance of the putative stem cell marker p63 in breast cancer
2009
AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.
2018
Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer
2010